Hereditary Cancer Panel denied as not medically necessary by Carelon (formerly AIM)?

NCCN-aligned for hereditary cancer testing. Pre-test genetic counseling required for many panels. Avalon overlap in some plans.

GC by ABGC-certified counselor (telegenetics qualifies). NCCN BOP/COL footnotes endorse multi-gene panels when >1 syndrome on differential. Reroute to in-network lab if denial is contractual.

## Why Carelon Denied Your Hereditary Cancer Panel as Not Medically Necessary

Carelon (formerly AIM Specialty Health) administers genetic testing prior authorization and medical necessity review for many health plans. A medical necessity denial means the clinical information submitted did not satisfy Carelon's coverage criteria for the hereditary cancer panel as documented. This is one of the most commonly appealed denial types for genetic testing — and one of the most frequently overturned when the right documentation is submitted.

## Why This Denial Is Appealable

Carelon's medical necessity criteria for hereditary cancer panels require specific clinical indicators: personal or family history features that meet guideline-based risk thresholds, a treating clinician's documented assessment, and confirmation that the results will influence clinical management. Denials at this stage often reflect missing documentation rather than a true absence of clinical need. Your prescriber's full clinical rationale — not just a code — is what wins these appeals.

## Federal Appeal Framework

• Internal Appeal: Under ACA and ERISA §503, you are entitled to a full-and-fair internal appeal. File within the deadline stated on your denial notice (commonly 180 days for ERISA plans).
• External Review: ACA §2719 provides the right to independent external review by an accredited IRO after a final internal denial. The external-review window is generally within four months of the final internal denial. An expedited review option exists for urgent clinical situations.
• ERISA Plans: Request the complete claims file and the specific coverage policy Carelon applied before drafting your appeal.

## Concrete Appeal Steps and Timeline

1. Request the denial letter and the specific clinical criteria applied — you need the exact policy language to map your documentation to it. 2. Meet with your prescriber to prepare a detailed medical-necessity letter addressing each criterion individually. 3. File internal appeal with all supporting documentation; confirm your plan's filing deadline. 4. File external review if internal appeal is denied — an IRO will evaluate whether Carelon's decision was consistent with generally accepted medical standards.

## Documentation to Gather

• Prescriber medical-necessity letter that addresses each of Carelon's stated criteria point by point
• Diagnosis confirmation records (pathology, imaging, biopsy results as applicable)
• Detailed personal and family cancer history with relationship to proband, cancer types, and ages at diagnosis
• Prior risk-assessment or genetic counseling documentation
• Evidence that results will change clinical management (e.g., surgical planning, surveillance protocol, treatment selection, or cascade testing for family members)
• Current applicable guideline from the relevant professional organization (such as NCCN), confirming the indication — obtain the current version directly from that organization

## Criteria-Mapping Structure

For each requirement in Carelon's published coverage policy, document the chart fact that satisfies it:

| Policy Requirement | Your Supporting Evidence | |---|---| | Clinical indication meets guideline-based risk criteria | Family history summary with specific cancers and relationships; risk-assessment documentation | | Ordering provider has assessed the clinical indication | Prescriber letter with clinical rationale | | Results will influence management | Prescriber's statement on how results will alter surveillance, treatment, or family counseling | | Genetic counseling addressed | Counseling note or prescriber attestation |

Every criterion that Carelon listed in the denial must have a corresponding documented answer. Incomplete mapping is the most common reason appeals fail at the internal level.